With the public availability of ChatGPT 3.5 in fall 2022 at the latest, artificial intelligence in the sense of large language models (LLMs) is on everyone’s lips. However, it is often forgotten that this is only the provisional end point of decades of development of artificial intelligence, which, despite its great potential, still has many limitations. The question for practising doctors is how this technology can be used sensibly in everyday clinical practice – and how it should not be used.
Autoren
- Dr. med. Lukas Dürst
- Dr. med. Marc Oertle
Publikation
- InFo RHEUMATOLOGIE
Related Topics
You May Also Like
- Psychedelic-assisted therapy
Current status of PAT
- Osgood-Schlatter Disease
Clinical Presentation, Diagnosis, and Treatment
- Cardiovascular Risk in Rheumatoid Arthritis
What is the most dangerous thing for RA?
- Antisense oligonucleotide for severe hypertriglyceridemia
Reduced Incidence of Acute Pancreatitis
- Hereditary Transthyretin Amyloidosis with Polyneuropathy
New Treatment Options for ATTRv-PN
- Type 1 Diabetes: A New Disease-Modifying Treatment Approach
Slowing the loss of β-cell function and delaying the progression of the disease
- Liver Cancer
Artificial Intelligence in Precision Oncology—Opportunities and Challenges
- Acute nonspecific back pain